Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ASPH | Q12797 | 2/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535033 | 0.87 | KEAP1 (0.50) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL29220966 | 0.81 | KEAP1 (0.48) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL9687559 | 0.80 | DGAT1 (0.42) | KEAP1NFE2L2KDM4ELMNAHSD17B10 | |
| SCHEMBL9805668 | 0.80 | SMN1; SMN2 (0.45) | KEAP1NFE2L2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL14325635 | 0.77 | KEAP1 (0.44) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL10469514 | 0.77 | KEAP1 (0.44) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL13285595 | 0.76 | IDO1 (0.44) | KEAP1KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL8751819 | 0.75 | CA12 (0.43) | KDM4ELMNACA1CA2ALDH1A1 | |
| SCHEMBL1713733 | 0.75 | KDM4E (0.54) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL4830274 | 0.75 | KEAP1 (0.54) | KEAP1NFE2L2KDM4EASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0655998-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2,6-DICHLORO-5-FLUORONICOTINIC ACID AND 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE | WARNER LAMBERT CO (US) | 1997-04-16 | — | — | EP | claimed |
| EP-2495243-B1 | NOVEL 5-FLUOROURACIL DERIVATIVE | DELTA-FLY PHARMA INC (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-8889699-B2 | 5-fluorouracil derivative | DELTA-FLY PHARMA, INC. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20120232103-A1 | NOVEL 5-FLUOROURACIL DERIVATIVE | DELTA-FLY PHARMA, INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-2495243-A1 | NOVEL 5-FLUOROURACIL DERIVATIVE | Delta-Fly Pharma, Inc. (JP) | 2012-09-05 | — | — | EP | disclosed |
| EP-0655998-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2,6-DICHLORO-5-FLUORONICOTINIC ACID AND 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE | WARNER LAMBERT CO (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0655998-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2,6-DICHLORO-5-FLUORONICOTINIC ACID AND 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE. | WARNER LAMBERT CO (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994004501-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2,6-DICHLORO-5-FLUORONICOTINIC ACID AND 2,6-DICHLORO-5-FLUORONICOTINOYL CHLORIDE | WARNER-LAMBERT COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5204478-A | Process for the synthesis of 2,6-dichloro-5-fluoronicotinic acid and 2,6-dichloro-5-fluoronicotinoyl chloride | WARNER-LAMBERT COMPANY (US) | 1993-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232103-A1 | NOVEL 5-FLUOROURACIL DERIVATIVE | DPYD, FAU, MTHFD1 | KEAP1 2127/4885NFE2L2 972/4885KDM4E 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.